NCT06270433View on ClinicalTrials.gov

Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets Versus Desvenlafaxine Succinate Sustained-release Tablets Targeting Anhedonia in Patients With Major Depression Disorder

NARecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

February 19, 2024

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Anhedonia
Interventions
DRUG

Toludesvenlafaxine hydrochloride sustained-release tablets

80 mg or 120 mg or 160 mg orally once daily dosing for 8 weeks

DRUG

Desvenlafaxine succinate sustained-release tablets

50 mg orally once daily dosing for 8 weeks

Trial Locations (1)

210024

RECRUITING

Nanjing Brian Hospital, Nanjing

All Listed Sponsors
lead

Jiangsu Province Nanjing Brain Hospital

OTHER